Preliminary Program

DAY 1 – Friday, October 14, 2022
All timing in CEST
10:00-10:10 Welcome Address by Congress chairs
10:10-11:10 Session 1: Keynote Lectures
Chairs: Judith Trotman, Australia & Stefano Luminari, Italy
10:10-10:30 What is the new classification bringing to the lymphoma landscape?
Daphne de Jong, Netherlands
10:30-10:50 How COVID impacts on risk-based selection of lymphoma care
Sean Lim, UK
10:50-11:10 Roundtable discussion
All speakers and chairs
11:10-12:10 Session 2: Can we do better in risk stratification of lymphoma patients?
Chairs: Judith Trotman, Australia & Stefano Luminari, Italy
11:10-11:30 Radiomics in lymphoma: TMTV, Dmax and beyond
TBA
11:30-11:50 Liquid biopsy in lymphomas: From technical aspects to its clinical use
Mark Roschewski, USA
11:50-12:10 Roundtable discussion
All speakers and chairs
12:10-13:10 Industry symposium timeslot
13:10-15:10 Session 3: Hodgkin’s lymphoma
Chairs: Mehdi Hamadani, USA & Anna Sureda, Spain
13:10-13:40 Debate: Should BV-AVD be the new standard of care for advanced stage cHL?
13:10–13:25 Yes: TBA
13:25–13:40 No: Paul Bröckelmann, Germany
13:40-14:10 Debate: Is radiotherapy still needed for early stage cHL?
13:40-13:55 Yes: Carmen Martinez, Spain
13:55-14:10 No: Wendy Osborne, UK
14:10-14:40 Debate: Triple refractory cHL (auto-HCT / BV / CPIs) are candidates for …
14:10-14:25 Allo-HCT: Carmello Carlo-Stella, Italy
14:25-14:40 CAR T cells: Sairah Ahmed, USA
14:40-15:10 Roundtable discussion
All speakers and chairs
15:10-17:10 Session 4: Large B cell lymphomas: First-line therapy
Chairs: Mehdi Hamadani, USA & Nilanjan Ghosh, USA
15:10-15:40 Debate: Is Pola-R-CHP the new standard of care for DLBCL?
15:10–15:25 Yes: Laurie Sehn, Canada
15:25–15:40 No: Nilanjan Ghosh, USA
15:40-16:10 Debate: Is R-DA-EPOCH the standard of care for double hit lymphomas?
15:40-15:55 Yes: Kieron Dunleavy, USA
15:55-16:10 No: Martina Pennisi, Italy
16:10-16:40 Debate: Should CNS prophylaxis be used in patients with high-risk aggressive B-cell lymphoma?
16:10-16:25 Yes: TBA
16:25-16:40 No: Matthew Wilson, UK
16:40-17:10 Roundtable discussion
All speakers and chairs
17:10-19:00 Session 5: Large B cell lymphomas: The relapse setting
Chairs: John Kuruvilla, Canada & Anna Sureda, Spain
17:10-17:20 Are improvements of salvage strategies in relapsed / refractory patients with DLBCL possible?
Christopher Fox, UK
17:20-17:50 Debate: Is CART cell therapy one-size-fits-all for primary refractory and early relapse patents with DLBCL?
17:20-17:35 Yes: TBA
17:35-17:50 No: Alberto Mussetti, Spain
17:50-18:20 Debate: Curing relapses after CART cell therapy
17:50-18:05 With BiEsp: Michael Dickinson, Australia
18:05-18:20 With Allo-HCT: Mazyar Shadman, USA
18:20-19:00 Roundtable discussion
All speakers and chairs
DAY 2 – Saturday, October 15, 2022
All timing in CEST
10:00-11:30 Session 6: Mantle cell lymphoma
Chairs: Marek Trněný, Czech Republic & Eva Giné, Spain
10:00-10:30 Debate: How will BTK inhibitors reshape first line therapy?
10:00-10:15 Young patients: Eliza Hawkes, Australia
10:15-10:30 Elderly patients: Mats Jerkeman, Sweden
10:30-11:00 Debate: Conquering MCL in Second line
10:30-10:45 BTK inhibitors: TBA
10:45-11:00 CAR T cells : Marie José Kersten, Netherlands
11:00-11:30 Roundtable discussion
All speakers and chairs
11:30-13:00 Session 7: CNS lymphomas
Chairs: Andres Ferreri, Italy & Gerald Illerhaus, Germany
11:30-12:00 Debate: Best induction therapy must include thiotepa
11:30-11:45 Yes: Kate Cwynarski, UK
11:45-12:00 No: TBA
12:00-12:30 Debate: Consolidation strategies in 1st CR should consider …
12:00-12:15 Auto-HCT: TBA
12:15-12:30 Radiotherapy: TBA
12:30-13:00 Roundtable discussion
All speakers and chairs
13:00-14:00 Industry symposium timeslot
14:00-16:10 Session 8: Follicular lymphoma
Chairs: Judith Trotman, Australia & Stefano Luminari, Italy
14:00-14:30 Debate: Is W&W still an option for newly diagnosed follicular lymphoma?
14:00-14:15 Yes: Elizabeth Phillips, UK
14:15-14:30 No: TBA
14:30-14:50 Chemo-free strategies as first-line therapy
Lia Palomba, USA
14:50-15:10 Towards a better identification of POD24 patients
Carla Casulo, USA
15:10-15:40 Debate: Is there any role for HCT in relapsed/refractory FL in 2022?
15:10-15:25 Yes: Timothy Fenske, USA
15:25-15:40 No: Caron Jacobson, USA
15:40-16:10 Roundtable discussion
All speakers and chairs
16:10-18:00 Session 9: Small lymphocytic lymphoma / Chronic lymphocytic leukemia
Chair: Toby Eyre, UK
16:10-16:40 Debate: Best first-line treatment strategy
16:10-16:20 BTK inhibitors: Farrukh Awan, USA
16:20-16:30 BCL-2 inhibitors: Mary Ann Anderson, Australia
16:30-16:40 Chemoimmunotherapy: TBA
16:40-17:00 Are MRD directed therapies ready for prime time?
Tanya Sidiqqi, USA
17:00-17:30 Debate: Best therapy for triple refractory SLL/CLL patients (BTKi, BCL-2, PI3Ki)
17:00-17:15 Allo-HCT: TBA
17:15-17:30 CAR T cells: TBA
17:30-18:00 Roundtable discussion
All speakers and chairs
18:00-18:15 Closing remarks by Congress chairs